The body composition profile is associated with response to anti‐<scp>TNF</scp> therapy in Crohn's disease and may offer an alternative dosing paradigm

Abstract

In this cohort study, body composition profiles did not correlate well with BMI. Myopenia was associated with primary nonresponse with potential implications for dosing and serves as an explanation for pharmacokinetic failure.